Antileishmanial activity of MDL 28170, a potent calpain inhibitor

[1]  T. Souto-Padrón,et al.  Phytomonas serpens: cysteine peptidase inhibitors interfere with growth, ultrastructure and host adhesion. , 2006, International journal for parasitology.

[2]  J. L. Martins,et al.  Insights into the role of gp63-like proteins in lower trypanosomatids. , 2006, FEMS microbiology letters.

[3]  H. Mehendale,et al.  Calpain: a death protein that mediates progression of liver injury. , 2005, Trends in pharmacological sciences.

[4]  Alane Beatriz Vermelho,et al.  Proteolytic expression in Blastocrithidia culicis: influence of the endosymbiont and similarities with virulence factors of pathogenic trypanosomatids , 2004, Parasitology.

[5]  A. L. Santos,et al.  Leishmanicidal activity of polyphenolic-rich extract from husk fiber of Cocos nucifera Linn. (Palmae). , 2004, Research in microbiology.

[6]  M. Otto,et al.  Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARSCoV) by Calpain Inhibitors and β-D-N4-Hydroxycytidine , 2004, Antiviral chemistry & chemotherapy.

[7]  Sarman Singh,et al.  Challenges and new discoveries in the treatment of leishmaniasis , 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[8]  Alane Beatriz Vermelho,et al.  A novel extracellular calcium-dependent cysteine proteinase from Crithidia deanei. , 2003, Archives of biochemistry and biophysics.

[9]  M. Kunimatsu,et al.  Calpain is involved in the HIV replication from the latently infected OM10.1 cells. , 2003, Biochemical and biophysical research communications.

[10]  O. Arancio,et al.  Calpain inhibitors, a treatment for alzheimer’s disease , 2002, Journal of molecular neuroscience : MN.

[11]  K. Gull,et al.  CAP5.5, a life-cycle-regulated, cytoskeleton-associated protein is a member of a novel family of calpain-related proteins in Trypanosoma brucei. , 2001, Molecular and biochemical parasitology.

[12]  V. Turk,et al.  The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease. , 2001, Current pharmaceutical design.

[13]  J. McKerrow,et al.  Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. , 1999, International journal for parasitology.

[14]  P. Desjeux,et al.  Global control and Leishmania HIV co-infection. , 1999, Clinics in dermatology.

[15]  G. Clifton,et al.  Potential contribution of proteases to neuronal damage. , 1998, Drug news & perspectives.

[16]  R. Nixon,et al.  Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease , 1997, Brain Research.

[17]  J. Krieglstein,et al.  Blockade of calpain proteolytic activity rescues neurons from glutamate excitotoxicity , 1997, Neuroscience Research.

[18]  M. Cotten,et al.  The adenovirus protease is required for virus entry into host cells. , 1995, Virology.

[19]  K. Saigo,et al.  Calpain localization changes in coordination with actin-related cytoskeleton changes during early embryonic development of Drosophila. , 1995, The Journal of Biological Chemistry.

[20]  R. Badaró,et al.  Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. , 1991, The American journal of tropical medicine and hygiene.